Figure 5.

β3 integrin labeling of Cre^+/− β3^flox/flox or Cre^−/− β3^flox/flox mice treated with or without tamoxifen. The TM-SC outflow pathway is outlined by the yellow dotted rectangle. The asterisk indicates SC. (A) Cre^+/− β3^flox/flox mouse treated with tamoxifen, (B) untreated Cre^+/− β3^flox/flox mouse. (C) Enlargement of the TM in (A). Open arrows indicate a lack of β3 integrin labeling. (D) Enlargement of the TM in (B). Closed arrows indicate β3 integrin labeling that is missing in (C). (E) Cre^−/− β3^flox/flox mouse treated with tamoxifen and (F) untreated Cre^−/− β3^flox/flox mouse. (G) Enlargement of the TM in (E). Closed arrows indicate β3 integrin labeling. (H) Enlargement of the TM in (F). Closed arrows indicate β3 integrin labeling. Micrographs are representative of several anterior segments. (A) n = 2, (B) n = 3, (C) n = 3, (D) n = 2. SC, Schlemm's canal. Scale bar: 20 μm.